Digi Power X Reports Solid Mid-Year Financial Position, Removal of ‘Going Concern' Risk and Positive Adjusted EBITDA in Q2 2025
MIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) — Digi Power X Inc. ('Digi Power X' or the 'Company') (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company specializing in Tier 3 AI data centers, high-performance computing and sustainable digital asset operations, today announced its unaudited financial results for the three and six months ended June 30, 2025 (all amounts in U.S. dollars, unless otherwise indicated). The Company's unaudited consolidated financial statements and management's discussion and analysis ('MD&A') for the three and six-month period ended June 30, 2025, have been filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and are also available on the SEC's EDGAR website at www.sec.gov/edgar.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 minutes ago
- Globe and Mail
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK , Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000 . Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000 . The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025 , and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025 , in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Cision Canada
33 minutes ago
- Cision Canada
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK, Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000. Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025, and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Globe and Mail
an hour ago
- Globe and Mail
5 Unstoppable "Ten Titans" Growth Stocks to Buy Now and Hold Through at Least 2030
Key Points The "Ten Titans" offer a more comprehensive list of top growth stocks than the "Magnificent Seven." Nvidia and Broadcom provide the building blocks of AI infrastructure. Microsoft, Alphabet, and Oracle are three exciting plays in cloud computing. 10 stocks we like better than Nvidia › The "Ten Titans" are the largest growth-focused U.S. companies by market cap -- consisting of Nvidia (NASDAQ: NVDA), Microsoft (NASDAQ: MSFT), Apple, Amazon, Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG), Meta Platforms, Broadcom (NASDAQ: AVGO), Tesla, Oracle (NYSE: ORCL), and Netflix. Combined, they make up over 37% of the S&P 500, showcasing the top-heavy nature of the index and how just a handful of companies can move the market. If I could only buy and hold half of the Ten Titans through 2030, I'd go with Nvidia, Broadcom, Microsoft, Oracle, and Alphabet. Here's what separates these growth stocks from the rest of the pack. The building blocks of AI Nvidia and Broadcom both play crucial roles in the buildout of artificial intelligence (AI). Nvidia's graphics processing units, CUDA software platform, and associated infrastructure provide a full-scale AI ecosystem for data centers. Orders continue to pour in for Nvidia's chips as big tech companies ramp up capital expenditures to support AI models. Broadcom makes application-specific integrated circuits, which are AI accelerators that can perform specific functions. The company's latest customer accelerator (XPU) is its 3.5D eXtreme Dimension System in Package, which drastically cuts down on power consumption and boosts efficiency between components -- all within a smaller package size. Broadcom offers compute, memory, network, and packaging capabilities, giving customers a vertically integrated solution for AI at scale. Broadcom has a highly differentiated networking and infrastructure software business. In addition to AI accelerators, its semiconductor segment also offers a variety of solutions for enterprise clients, like broadband, wireless, storage, and more. Three different ways to bet on cloud computing Microsoft, Alphabet, and Oracle offer three distinctly different ways to invest in cloud computing. Microsoft Azure is the No. 2 cloud player behind Amazon Web Services. Azure is Microsoft's fastest-growing segment -- capitalizing on AI demand through cloud offerings specifically geared toward handling AI workloads. But what separates Microsoft from other cloud plays is the strength of the rest of its business. Copilot for Azure, the Microsoft 365 software suite, and GitHub continue to grow their active user base. Microsoft's revenue growth has accelerated, and profit margins are at their highest level in over a decade -- driving Microsoft's surging stock price. Alphabet's Google Cloud doesn't have as much market share as Azure, but it is growing quickly and becoming more profitable. But unlike Microsoft, where cloud is the centerpiece of the investment thesis, Google Cloud doesn't contribute nearly as much to Alphabet's bottom line as other services -- namely Google Search and YouTube. Alphabet stock has roared higher in recent months, but it's still arguably the best value of the Ten Titans. TSLA PE Ratio (Forward) data by YCharts While Google Search could see disruption from rival information resources like ChatGPT, it's worth noting that Google Gemini has gained significant traction in recent quarters -- showing Alphabet's ability to adapt. Oracle Cloud Infrastructure (OCI) is arguably the most exciting play in cloud computing right now. OCI is thriving due to its flexible structure, which leans on Oracle's established database ecosystem. It is best paired with Oracle databases and applications, with certain services not available on other clouds. Instead of going toe-to-toe with the "big three" cloud providers, Oracle partners with them by combining its database services with the AWS, Azure, and Google Cloud infrastructure. All told, Oracle is a top play in cloud computing because it offers its own vertically integrated suite of solutions, but also stands to benefit from the overall growth of the industry through its partnerships. These titans are worth their premium price tags Nvidia, Broadcom, Microsoft, Alphabet, and Oracle have all been phenomenal stocks -- crushing the S&P 500 over the last five years. With the exception of Alphabet, outsized gains have made valuations expensive based on their trailing and forward earnings estimates, which may deter some investors from approaching these names. However, folks who are looking for top companies to buy and hold through at least 2030 will care more about where a company will be years from now than the next few quarters. The advantage of a longer investment time horizon is that you can give a company time to grow into its valuation. Nvidia, Broadcom, and Oracle are some of the most expensive of the Ten Titans, but they also have the most attractive runways for growth. Meanwhile, Microsoft and Alphabet have more reasonable valuations and multiple levers to pull for growing earnings for years to come. There are valid cases for buying all of the Ten Titans, but Nvidia, Broadcom, Microsoft, Alphabet, and Oracle truly stand out as the best of the best for long-term investors. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Foelber has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Netflix, Nvidia, Oracle, and Tesla. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
